Comparison of covered stents versus bare metal stents for treatment of chronic atherosclerotic mesenteric arterial disease

Gustavo Oderich, Luke S. Erdoes, Christopher Lesar, Bernardo C. Mendes, Peter Gloviczki, Stephen Cha, Audra A. Duncan, Thomas C. Bower

Research output: Contribution to journalArticle

58 Citations (Scopus)

Abstract

Objective: To compare outcomes of mesenteric angioplasty and stenting using iCAST covered stents (CS; Atrium, Hudson, NH) or bare metal stents (BMS) in patients with chronic mesenteric ischemia (CMI). Methods: We reviewed the clinical data of 225 patients (65 male and 160 female; mean age, 72 ± 12 years) treated for CMI at two academic centers (2000-2010). Outcomes were analyzed in patients who had primary intervention or reintervention using BMS (n = 164 patients/197 vessels) or CS (n = 61 patients/67 vessels). End points were freedom from restenosis, symptom recurrence, reinterventions, and patency rates. Results: Patients in both groups had similar demographics, cardiovascular risk factors, and extent of disease. In the primary intervention group (mean follow-up, 29 ± 12 months), patients treated by CS had higher freedom from restenosis (92% ± 6% vs 53% ± 4%; P =.003), symptom recurrence (92 ± 4% vs 50 ± 5%; P =.003), reintervention (91% ± 6% vs 56% ± 5%; P =.005), and better primary patency at 3 years (92% ± 6% vs 52% ± 5%; P <.003) than for BMS. In the reintervention group (mean follow-up, 24 ± 9 months), patients treated by CS had higher freedom from restenosis (89% ± 10% vs 49% ± 14%; P <.04), symptom recurrence (100% vs 64%± 9%; P =.001), and reintervention (100% vs 72% ± 9%; P =.03) at 1 year, and a trend toward improved primary patency at 1 year (100% vs 63% ± 9%; P =.054). Secondary patency rates were similar in both groups. Conclusions: In this nonrandomized study, CS were associated with less restenosis, recurrences, and reinterventions than BMS in patients undergoing primary interventions or reinterventions for CMI.

Original languageEnglish (US)
Pages (from-to)1316-1323
Number of pages8
JournalJournal of Vascular Surgery
Volume58
Issue number5
DOIs
StatePublished - Nov 1 2013

Fingerprint

Stents
Metals
Recurrence
Therapeutics
Angioplasty
Demography
Mesenteric Ischemia

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Surgery

Cite this

Comparison of covered stents versus bare metal stents for treatment of chronic atherosclerotic mesenteric arterial disease. / Oderich, Gustavo; Erdoes, Luke S.; Lesar, Christopher; Mendes, Bernardo C.; Gloviczki, Peter; Cha, Stephen; Duncan, Audra A.; Bower, Thomas C.

In: Journal of Vascular Surgery, Vol. 58, No. 5, 01.11.2013, p. 1316-1323.

Research output: Contribution to journalArticle

Oderich, Gustavo ; Erdoes, Luke S. ; Lesar, Christopher ; Mendes, Bernardo C. ; Gloviczki, Peter ; Cha, Stephen ; Duncan, Audra A. ; Bower, Thomas C. / Comparison of covered stents versus bare metal stents for treatment of chronic atherosclerotic mesenteric arterial disease. In: Journal of Vascular Surgery. 2013 ; Vol. 58, No. 5. pp. 1316-1323.
@article{34a8262b445343f28ceabfb170d273ce,
title = "Comparison of covered stents versus bare metal stents for treatment of chronic atherosclerotic mesenteric arterial disease",
abstract = "Objective: To compare outcomes of mesenteric angioplasty and stenting using iCAST covered stents (CS; Atrium, Hudson, NH) or bare metal stents (BMS) in patients with chronic mesenteric ischemia (CMI). Methods: We reviewed the clinical data of 225 patients (65 male and 160 female; mean age, 72 ± 12 years) treated for CMI at two academic centers (2000-2010). Outcomes were analyzed in patients who had primary intervention or reintervention using BMS (n = 164 patients/197 vessels) or CS (n = 61 patients/67 vessels). End points were freedom from restenosis, symptom recurrence, reinterventions, and patency rates. Results: Patients in both groups had similar demographics, cardiovascular risk factors, and extent of disease. In the primary intervention group (mean follow-up, 29 ± 12 months), patients treated by CS had higher freedom from restenosis (92{\%} ± 6{\%} vs 53{\%} ± 4{\%}; P =.003), symptom recurrence (92 ± 4{\%} vs 50 ± 5{\%}; P =.003), reintervention (91{\%} ± 6{\%} vs 56{\%} ± 5{\%}; P =.005), and better primary patency at 3 years (92{\%} ± 6{\%} vs 52{\%} ± 5{\%}; P <.003) than for BMS. In the reintervention group (mean follow-up, 24 ± 9 months), patients treated by CS had higher freedom from restenosis (89{\%} ± 10{\%} vs 49{\%} ± 14{\%}; P <.04), symptom recurrence (100{\%} vs 64{\%}± 9{\%}; P =.001), and reintervention (100{\%} vs 72{\%} ± 9{\%}; P =.03) at 1 year, and a trend toward improved primary patency at 1 year (100{\%} vs 63{\%} ± 9{\%}; P =.054). Secondary patency rates were similar in both groups. Conclusions: In this nonrandomized study, CS were associated with less restenosis, recurrences, and reinterventions than BMS in patients undergoing primary interventions or reinterventions for CMI.",
author = "Gustavo Oderich and Erdoes, {Luke S.} and Christopher Lesar and Mendes, {Bernardo C.} and Peter Gloviczki and Stephen Cha and Duncan, {Audra A.} and Bower, {Thomas C.}",
year = "2013",
month = "11",
day = "1",
doi = "10.1016/j.jvs.2013.05.013",
language = "English (US)",
volume = "58",
pages = "1316--1323",
journal = "Journal of Vascular Surgery",
issn = "0741-5214",
publisher = "Mosby Inc.",
number = "5",

}

TY - JOUR

T1 - Comparison of covered stents versus bare metal stents for treatment of chronic atherosclerotic mesenteric arterial disease

AU - Oderich, Gustavo

AU - Erdoes, Luke S.

AU - Lesar, Christopher

AU - Mendes, Bernardo C.

AU - Gloviczki, Peter

AU - Cha, Stephen

AU - Duncan, Audra A.

AU - Bower, Thomas C.

PY - 2013/11/1

Y1 - 2013/11/1

N2 - Objective: To compare outcomes of mesenteric angioplasty and stenting using iCAST covered stents (CS; Atrium, Hudson, NH) or bare metal stents (BMS) in patients with chronic mesenteric ischemia (CMI). Methods: We reviewed the clinical data of 225 patients (65 male and 160 female; mean age, 72 ± 12 years) treated for CMI at two academic centers (2000-2010). Outcomes were analyzed in patients who had primary intervention or reintervention using BMS (n = 164 patients/197 vessels) or CS (n = 61 patients/67 vessels). End points were freedom from restenosis, symptom recurrence, reinterventions, and patency rates. Results: Patients in both groups had similar demographics, cardiovascular risk factors, and extent of disease. In the primary intervention group (mean follow-up, 29 ± 12 months), patients treated by CS had higher freedom from restenosis (92% ± 6% vs 53% ± 4%; P =.003), symptom recurrence (92 ± 4% vs 50 ± 5%; P =.003), reintervention (91% ± 6% vs 56% ± 5%; P =.005), and better primary patency at 3 years (92% ± 6% vs 52% ± 5%; P <.003) than for BMS. In the reintervention group (mean follow-up, 24 ± 9 months), patients treated by CS had higher freedom from restenosis (89% ± 10% vs 49% ± 14%; P <.04), symptom recurrence (100% vs 64%± 9%; P =.001), and reintervention (100% vs 72% ± 9%; P =.03) at 1 year, and a trend toward improved primary patency at 1 year (100% vs 63% ± 9%; P =.054). Secondary patency rates were similar in both groups. Conclusions: In this nonrandomized study, CS were associated with less restenosis, recurrences, and reinterventions than BMS in patients undergoing primary interventions or reinterventions for CMI.

AB - Objective: To compare outcomes of mesenteric angioplasty and stenting using iCAST covered stents (CS; Atrium, Hudson, NH) or bare metal stents (BMS) in patients with chronic mesenteric ischemia (CMI). Methods: We reviewed the clinical data of 225 patients (65 male and 160 female; mean age, 72 ± 12 years) treated for CMI at two academic centers (2000-2010). Outcomes were analyzed in patients who had primary intervention or reintervention using BMS (n = 164 patients/197 vessels) or CS (n = 61 patients/67 vessels). End points were freedom from restenosis, symptom recurrence, reinterventions, and patency rates. Results: Patients in both groups had similar demographics, cardiovascular risk factors, and extent of disease. In the primary intervention group (mean follow-up, 29 ± 12 months), patients treated by CS had higher freedom from restenosis (92% ± 6% vs 53% ± 4%; P =.003), symptom recurrence (92 ± 4% vs 50 ± 5%; P =.003), reintervention (91% ± 6% vs 56% ± 5%; P =.005), and better primary patency at 3 years (92% ± 6% vs 52% ± 5%; P <.003) than for BMS. In the reintervention group (mean follow-up, 24 ± 9 months), patients treated by CS had higher freedom from restenosis (89% ± 10% vs 49% ± 14%; P <.04), symptom recurrence (100% vs 64%± 9%; P =.001), and reintervention (100% vs 72% ± 9%; P =.03) at 1 year, and a trend toward improved primary patency at 1 year (100% vs 63% ± 9%; P =.054). Secondary patency rates were similar in both groups. Conclusions: In this nonrandomized study, CS were associated with less restenosis, recurrences, and reinterventions than BMS in patients undergoing primary interventions or reinterventions for CMI.

UR - http://www.scopus.com/inward/record.url?scp=84886598232&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84886598232&partnerID=8YFLogxK

U2 - 10.1016/j.jvs.2013.05.013

DO - 10.1016/j.jvs.2013.05.013

M3 - Article

C2 - 23827340

AN - SCOPUS:84886598232

VL - 58

SP - 1316

EP - 1323

JO - Journal of Vascular Surgery

JF - Journal of Vascular Surgery

SN - 0741-5214

IS - 5

ER -